Sanofi SA said Monday that it will acquire biotechnology company Synthorx Inc. for an aggregated equity value of around $2.5 billion.
The French pharmaceutical company SAN, -0.48% SNY, -0.11% said it plans to take control of all outstanding shares of Synthorx THOR, +0.20% for $68 per share in cash.
The acquisition of Synthorx, which is expected to close in the first quarter next year, will strengthen Sanofi’s existing immuno-oncology portfolio, it said.
The takeover is “aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations,” Sanofi’s Chief Executive Paul Hudson said.
https://news.google.com/__i/rss/rd/articles/CBMiXmh0dHBzOi8vd3d3Lm1hcmtldHdhdGNoLmNvbS9zdG9yeS9zYW5vZmktdG8tYWNxdWlyZS1zeW50aG9yeC1mb3ItMjUtYmlsbGlvbi0yMDE5LTEyLTA5LTIxMDM4NDLSAU9odHRwczovL3d3dy5tYXJrZXR3YXRjaC5jb20vYW1wL3N0b3J5L2d1aWQvMjVENTQ2REUtMUE1Mi0xMUVBLUIwNEMtMUIxMEEzMTQ3ODNF?oc=5
2019-12-09 09:07:00Z
CAIiEMFbhFJmxQqgJiiDkTOn52EqGAgEKg8IACoHCAowjujJATDXzBUwiJS0AQ
Bagikan Berita Ini
0 Response to "Sanofi to acquire Synthorx for $2.5 billion - MarketWatch"
Post a Comment